Boehringer Ingelheim Venture Fund co-led the cancer immunotherapy developer's series A round, which also featured Illumina Ventures.

Pharmaceutical firm Boehringer Ingelheim’s Venture Fund (BIVF) co-led a $34m series A round for Actym Therapeutics, a US-based immuno-oncology drug developer allied to University of California, Berkeley, on Monday.

Healthcare-focused venture capital firm Panacea Venture co-led the round, which included Illumina Ventures, the investment arm of genomic technology provider Illumina, as well as Korea Investment Partners and JLo Ventures.

Founded in 2017, Actym is working on intravenous cancer immunotherapies that target immune cells in the microenvironment of multiple tumour subtypes.

…